Orapred ODT

Orapred ODT is a brand name of prednisolone, approved by the FDA in the following formulation(s):

ORAPRED ODT (prednisolone sodium phosphate - tablet, orally disintegrating; oral)

• 
  Manufacturer: SHIONOGI INC
  
  Approval date: June 1, 2006
  
  Strength(s): EQ 10MG BASE, EQ 15MG BASE, EQ 30MG BASE ^[RLD]

Has a generic version of Orapred ODT been approved?

No. There is currently no therapeutically equivalent version of Orapred ODT available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Orapred ODT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Rapidly dissolving robust dosage form
  Patent 6,024,981
  Issued: February 15, 2000
  Inventor(s): Khankari; Rajendra K. & Hontz; John & Chastain; Sara J. & Katzner; Leo
  Assignee(s): Cima Labs Inc.
  The invention is directed to a hard tablet that can be stored, packaged and processed in bulk. Yet the tablet dissolves rapidly in the mouth of the patient with a minimum of grit. The tablet is created from an active ingredient mixed into a matrix of a non-direct compression filler and a relatively high lubricant content.
  
  Patent expiration dates:
  
  
  • April 9, 2018
    
    ✓ 
    Drug product
    ✓ 
    Sponsor has requested patent be delisted
  
  



• 
  Rapidly dissolving robust dosage form
  Patent 6,221,392
  Issued: April 24, 2001
  Inventor(s): Khankari; Rajendra K. & Hontz; John & Chastain; Sara J. & Katzner; Leo
  Assignee(s): Cima Labs Inc.
  The invention is directed to a hard tablet that can be stored, packaged and processed in bulk. Yet the tablet dissolves rapidly in the mouth of the patient with a minimum of grit. The tablet is created from an active ingredient mixed into a matrix of a nondirect compression filler and a relatively high lubricant content.
  
  Patent expiration dates:
  
  
  • April 9, 2018
    
    ✓ 
    Drug product
    ✓ 
    Sponsor has requested patent be delisted
  
  



• 
  Taste masking rapid release coating system
  Patent 6,740,341
  Issued: May 25, 2004
  Inventor(s): Kris E.; Holt & Rajendra K.; Khankari & John; Hontz
  Assignee(s): Cima Labs Inc.
  The present invention relates to a core containing a drug encased in a spacing layer and a taste masking layer which provides effective taste masking for in-mouth disintegrable dosage forms containing highly objectionable tasting drugs, as well as dosage forms containing these cores.
  
  Patent expiration dates:
  
  
  • November 24, 2019
    
    ✓ 
    Drug product
  
  

See also...

• Orapred ODT Consumer Information (Wolters Kluwer)
• Orapred ODT Consumer Information (Cerner Multum)
• Prednisolone Consumer Information (Wolters Kluwer)
• Prednisolone Acetate Suspension Consumer Information (Wolters Kluwer)
• Prednisolone Sodium Phosphate Consumer Information (Wolters Kluwer)
• Prednisolone Sodium Phosphate Liquid Consumer Information (Wolters Kluwer)
• Prednisolone Sodium Phosphate Solution Consumer Information (Wolters Kluwer)
• Prednisolone Syrup Consumer Information (Wolters Kluwer)
• Prednisolone Consumer Information (Cerner Multum)
• Prednisolone AHFS DI Monographs (ASHP)
• Prednisolone Sodium Phosphate AHFS DI Monographs (ASHP)